These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3953608)

  • 21. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Epstein RA
    Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
    [No Abstract]   [Full Text] [Related]  

  • 22. Control of investigation drugs in a research hospital.
    Kleinman LM; Tangrea JA; Gallelli JF
    Am J Hosp Pharm; 1974 Apr; 31(4):368-71. PubMed ID: 4822026
    [No Abstract]   [Full Text] [Related]  

  • 23. The Food and Drug Administration and its problems.
    Iglehart JK
    N Engl J Med; 1991 Jul; 325(3):217-20. PubMed ID: 2052069
    [No Abstract]   [Full Text] [Related]  

  • 24. Maker of growth hormone feels long arm of law.
    Nordenberg T
    FDA Consum; 1999; 33(5):33. PubMed ID: 10522170
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmaceuticals must be controlled by the pharmacy.
    Davis NM
    Hosp Pharm; 1987 Jan; 22(1):8, 11. PubMed ID: 10280295
    [No Abstract]   [Full Text] [Related]  

  • 26. Research regulation, and development of new pharmaceuticals: past, present, and future. 1.
    Lasagna L
    Am J Med Sci; 1972 Jan; 263(1):9-18. PubMed ID: 4257990
    [No Abstract]   [Full Text] [Related]  

  • 27. Policy and procedure manual. Drug recall program.
    Curr Concepts Hosp Pharm Manage; 1984; 6(3):19. PubMed ID: 10267189
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving and enforcing compounding pharmacy practices to protect patients.
    Pegues DA
    Clin Infect Dis; 2006 Oct; 43(7):838-40. PubMed ID: 16941363
    [No Abstract]   [Full Text] [Related]  

  • 29. Research, regulation and development of new pharmaceuticals: past, present and future. II.
    Lasagna L
    Am J Med Sci; 1972 Feb; 263(2):66-78. PubMed ID: 5017858
    [No Abstract]   [Full Text] [Related]  

  • 30. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
    Willis KD
    Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacy directors fear that anti-resale law may be point of no return for drugs.
    Wagner M
    Mod Healthc; 1988 Sep; 18(40):38. PubMed ID: 10290435
    [No Abstract]   [Full Text] [Related]  

  • 32. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
    Lexchin J
    CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
    [No Abstract]   [Full Text] [Related]  

  • 34. Drugs and the Washington climate.
    Durant TM
    Trans Am Clin Climatol Assoc; 1969; 80():196-204. PubMed ID: 4896316
    [No Abstract]   [Full Text] [Related]  

  • 35. ASHP guidelines for the use of investigational drugs in institutions.
    Am J Hosp Pharm; 1983 Mar; 40(3):449-51. PubMed ID: 6846357
    [No Abstract]   [Full Text] [Related]  

  • 36. Rules for evaluating biosimilars put applicants through hoops.
    Morrow T
    Manag Care; 2012 Mar; 21(3):56-7. PubMed ID: 22471166
    [No Abstract]   [Full Text] [Related]  

  • 37. DEA authority to levy fine for noncompliance with controlled-substance records.
    Ensor PA
    Am J Hosp Pharm; 1992 Jan; 49(1):38, 44. PubMed ID: 1570864
    [No Abstract]   [Full Text] [Related]  

  • 38. Application of the Food and Drug Administration's current good manufacturing practices regulations to pharmacy practice: a legal view.
    Fink JL
    Contemp Pharm Pract; 1979; 2(4):202-5. PubMed ID: 10244540
    [No Abstract]   [Full Text] [Related]  

  • 39. ASHP guidelines on managing drug product shortages.
    ASHP Council on Administrative Affairs, American Society of Health-System Pharmacists
    Am J Health Syst Pharm; 2001 Aug; 58(15):1445-50. PubMed ID: 11494791
    [No Abstract]   [Full Text] [Related]  

  • 40. Lawful uses of drugs purchased at preferential prices.
    Szeinbach SL; Fink JL
    Hosp Pharm; 1985 Jan; 20(1):24-8. PubMed ID: 10269764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.